[{"id":"1d8c8a20-aa7c-47e4-aa25-c755f938afd8","acronym":"LACEWING","url":"https://clinicaltrials.gov/study/NCT02752035","created_at":"2021-01-17T17:23:14.096Z","updated_at":"2024-07-02T16:34:26.721Z","phase":"Phase 3","brief_title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","source_id_and_acronym":"NCT02752035 - LACEWING","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 183","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-06-12"},{"id":"f66040f9-40e2-41bd-8c69-4d4ef3afbdf1","acronym":"COMMODORE","url":"https://clinicaltrials.gov/study/NCT03182244","created_at":"2021-01-18T15:41:35.073Z","updated_at":"2024-07-02T16:35:01.009Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation","source_id_and_acronym":"NCT03182244 - COMMODORE","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 01/15/2018","start_date":" 01/15/2018","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-24"},{"id":"7b7c91a6-9486-4633-b3e2-ffef9fa008f4","acronym":"ADMIRAL","url":"https://clinicaltrials.gov/study/NCT02421939","created_at":"2021-01-17T17:23:13.438Z","updated_at":"2024-07-02T16:35:01.814Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","source_id_and_acronym":"NCT02421939 - ADMIRAL","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 10/20/2015","start_date":" 10/20/2015","primary_txt":" Primary completion: 09/17/2018","primary_completion_date":" 09/17/2018","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-23"},{"id":"a1b1a802-1353-41c5-80f6-98719e12dcd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05520567","created_at":"2022-08-30T20:55:48.582Z","updated_at":"2024-07-02T16:35:01.630Z","phase":"Phase 1/2","brief_title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05520567","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/27/2023","start_date":" 01/27/2023","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-05-23"},{"id":"370a32d3-7f84-4b34-a0c4-86832be5fec0","acronym":"FRIDA","url":"https://clinicaltrials.gov/study/NCT05546580","created_at":"2022-09-21T21:56:59.855Z","updated_at":"2024-07-02T16:35:18.799Z","phase":"Phase 1","brief_title":"Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)","source_id_and_acronym":"NCT05546580 - FRIDA","lead_sponsor":"Oryzon Genomics S.A.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2024-02-19"},{"id":"1ae89bb9-e654-4cae-adf5-e98fed55013d","acronym":"OGILAR","url":"https://clinicaltrials.gov/study/NCT06022003","created_at":"2023-09-01T17:11:43.343Z","updated_at":"2024-07-02T16:35:20.705Z","phase":"Phase 2","brief_title":"Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT06022003 - OGILAR","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/13/2024","start_date":" 01/13/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-02-06"},{"id":"192b121c-dfa2-4eff-ae2b-d136c65ef93b","acronym":" UNIFY","url":"https://clinicaltrials.gov/study/NCT03512197","created_at":"2021-01-18T17:17:13.296Z","updated_at":"2024-07-02T16:35:39.473Z","phase":"Phase 3","brief_title":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT03512197 -  UNIFY","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 D835 • FLT3 I836","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 511","initiation":"Initiation: 07/20/2018","start_date":" 07/20/2018","primary_txt":" Primary completion: 02/12/2021","primary_completion_date":" 02/12/2021","study_txt":" Completion: 02/12/2021","study_completion_date":" 02/12/2021","last_update_posted":"2023-08-21"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"f4922af1-9387-4965-9097-6bb80a183fca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03324243","created_at":"2021-01-18T16:24:57.273Z","updated_at":"2024-07-02T16:37:04.008Z","phase":"Phase 2","brief_title":"A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03324243","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • fludarabine IV"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-01-10"},{"id":"657e0a9a-93ab-43d4-8294-14338ced7333","acronym":"","url":"https://clinicaltrials.gov/study/NCT03409081","created_at":"2021-01-18T16:49:10.594Z","updated_at":"2024-07-02T16:37:06.961Z","phase":"","brief_title":"Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)","source_id_and_acronym":"NCT03409081","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2018-09-13"}]